Thyroid hormone and breast carcinoma: Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma

Cancer

Volumn 103, Issue 6, 2005, Pages 1122-1128

  Cristofanilli, Massimo ^a   Yamamura, Yuko ^a   Kau, Shu Wan ^a   Bevers, Therese ^a   Strom, Sara ^a   Patangan, Modesto ^a   Hsu, Limin ^a   Krishnamurthy, Savitri ^a   Theriault, Richard L ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast carcinoma; Hypothyroidism; Menopausal status; Risk factor

Indexed keywords

ESTROGEN RECEPTOR; LEVOTHYROXINE; THYROID HORMONE; THYROXINE;

AGE DETERMINATION; BREAST CARCINOMA; CANCER SCREENING; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ETHNOLOGY; HORMONAL THERAPY; HUMAN; HYPOTHYROIDISM; INCIDENCE; MENOPAUSE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; TUMOR VOLUME;

ADULT; AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; HUMANS; HYPOTHYROIDISM; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; REFERENCE VALUES; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THYROID FUNCTION TESTS; THYROID HORMONES; THYROXINE;

EID: 20044370107     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20881     Document Type: Review

References (32)

1. Werner SC. Classification of thyroid diseases. Report of the committee on nomenclature. American Thyroid Association. J Clin Endocrinol Metab. 1969;29:860-862.
2. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896;2:104-107.
3. Nogueira CR, Brentani MM. Triiodothyronine mimics the effect of estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol. 1996;59:271-279.
4. Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene. 2002;21:761-768.
5. Vonderhaar BK, Greco AE. Lobulo-alveolar development of mouse mammary glands is regulated by thyroid hormones. Endocrinology. 1979;104:409-418.
6. Brinton LA, Hoffman DA, Hoover R, Fraumeni JF Jr. Relationship of thyroid disease and use of thyroid supplements to breast cancer risk. J Chron Dis. 1984;37:877-893.
7. Simon MS, Tang MT, Bernstein L, et al. Do thyroid disorders increase the risk of breast cancer? Cancer Epidemiol Biomarkers Prev. 2002;11:1574-1578.
8. Franceschi S, La Vecchia C, Negri E, Parazzini F, Boyle P. Breast cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer. 1990;26:781-785.
9. Altieri A, Tavani A, Gallus S, et al. Correspondence re: Simon et al. Do thyroid disorders increase the risk of breast cancer? 11:1574-1578, 2002. Cancer Epidemiol Biomarkers Prev. 2002;12:684-686.
10. Ellerker AG. Thyroid disorders and breast cancer. A causal connection? Med Press. 1956;235:280-282.
11. Itoh K, Maruchi N. Breast cancer in patients with Hashimoto's thyroiditis. Lancet. 1975;2:1109-1112.
12. Shering SG, Zbar AP, Moriarty M, McDermott EWM, O'Higgins NJ, Smith PPA. Thyroid disorders and breast cancer. Eur J Cancer Prev. 1996;5:504-506.
13. Smith PPA, Shering SG, Kilbane MT, et al. Serum thyroid peroxidase autoantibodies, thyroid volume and outcome in breast carcinoma. J Clin Endocrinol Metab. 1998;83:2711-2716.
14. Roberts GP, Ladenson PW. Hypothyroidism. Lancet. 2004;363:793-803.
15. Gail MH, Benichou J. Validation studies on a model for breast cancer risk. J Natl Cancer Inst. 1994;86:573-575.
16. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419-427. Erratum in: Lancet. 2003;362:1160.
17. Venturi S, Donati FM, Venturi A, et al. Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach. Adv Clin Pathol. 2000;4:11-17.
18. Kilbane MT, Ajjan RA, Weetman AP, et al. Tissue iodine content and serum-mediated 1251 uptake-blocking activity in breast cancer. J Clin Endocrinol Metab. 2000;3:1245-1250.
19. Vonderhaar BK, Tang E, Lyster RR, Nascimento MC. Thyroid hormone regulation of epidermal growth factor receptor levels in mouse mammary glands. Endocrinology. 1986;119:580-585.
20. Bhattacharya A, Vonderhaar BK. Specific binding proteins for 3, 5, 30-triiodothyronine in mouse mammary epithelium. J Cell Biol. 1977;75:47a.
21. Selliti D, Tseng Y, Latham K. Nuclear thyroid hormone receptors in C3H/HeN mouse mammary glands and spontaneous tumors. Cancer Res. 1983;43:1030-1038.
22. Smallridge RC, Latham KR. Nuclear thyroid hormone receptor in human breast tumors. Clin Res. 1980;28:421.
23. Cerbon M-A, Pichon M-F, Milgrom E. Thyroid hormone receptors in human breast cancer. Cancer Res. 1981;41:4167-4173.
24. Kupper FC, Schweigert N, Ar Gall E, et al. Iodine uptake in Laminariales involves extracellular, haloperoxidase-mediated oxidation of iodide. Planta. 1998;207:163-171.
25. van de Vijver M, van de Bersselaar R, Devilee P, et al. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 1987;7:2019-2023.
26. Li Z, Meng ZH, Chandrasekaran R, et al. Biallelic inactivation of the thyroid hormone receptor beta 1 gene in early stage breast cancer. Cancer Res. 2002;62:1939-1943.
27. Silva JM, Dominguez G, Gonzalez-Sancho JM, et al. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene. 2002;21:4307-4316.
28. Martinez MB, Ruan M, Fitzpatrick LA. Altered response to thyroid hormones by breast and ovarian cancer cells. Anticancer Res. 2000;20:4141-4146.
29. Gonzalez-Sancho JM, Figueroa A, Lopez-Barahona M, et al. Inhibition of proliferation and expression of T1 and cyclin D1 genes by thyroid hormone in mammary epithelial cells. Mol Carcinog. 2002;34:25-34.
30. Glass CK. Differential recognition of target genes by nuclear receptor monomers, dimmers and heterodimers. Endocrine Rev. 1994;15:391-407.
31. 3-receptor/retinoid X receptor heterodimer binding to DNA. J Biol Chem. 1992;267:23248-23252.
32. D'Cruz CM, Moody SE, Master SR, et al. Persistent parity-induced changes in growth factors, TGF-β3, and differentiation in the rodent mammary gland. Mol Endocrinol. 2002;16:2034-2051.